Zydus Lifesciences and Lupin have entered into a licensing and supply agreement to co-market semaglutide injections in India, positioning themselves ahead of the drug’s upcoming patent expiry. Semaglutide, a GLP-1 receptor agonist, is widely used for treating Type 2 diabetes and has gained popularity for weight management due to its ability to regulate blood sugar […]Continue Reading
